What is CJC-1295 No DAC?
CJC-1295 No DAC is a substituted analog of the first 29 residues of human growth hormone releasing factor, with an amidated C-terminus. It is also sold as modified growth hormone releasing factor 1 to 29. It shares its backbone with CJC-1295 with DAC but lacks the C-terminal lysine carrying a maleimide group, the drug affinity complex that lets the named compound bind albumin in circulation (Jetté et al., 2005).
That one difference separates two compounds with very different published records. Disguised Alpha supplies CJC-1295 No DAC as a lyophilized powder for laboratory research use only. Nothing on this page is guidance for use in people.
CJC-1295 No DAC reference data
| Property | Value |
|---|---|
| Name | CJC-1295 No DAC |
| Also called | Modified growth hormone releasing factor (1 to 29), amidated |
| Backbone | Human growth hormone releasing factor residues 1 to 29, with substitutions at positions 2 (D-alanine), 8 (glutamine), 15 (alanine) and 27 (leucine) |
| Peptide class | Releasing factor analog, 29 residues |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367.9 g/mol |
| CAS number | 863288-34-0 (PubChem CID 56841945) |
| Form | Lyophilized powder |
| Testing | Third-party tested, with the certificate for each lot published on the product page and in the COA portal |
Formula, molecular weight and CAS number are from the CJC-1295 No DAC product page; the substitutions are from the PubChem sequence records. Public synonym lists for these compounds are not clean: the PubChem entry carrying CAS 863288-34-0 also lists names belonging to the version with DAC. Identify material by formula, molecular weight and the identity printed on the lot certificate, never by trade name alone.
What the research covers
Most published work concerns either the native releasing factor fragment or the version with DAC. This guide keeps those apart and states the model for every finding.
Why the backbone is substituted
Native growth hormone releasing factor is cleaved at its amino terminus by a plasma dipeptidylaminopeptidase into a product with under one thousandth of the parent's activity (Frohman et al., 1986). Dipeptidyl peptidase IV does not cleave substrates that carry a D-configuration residue at that position (Bongers et al., 1992), and in healthy men a D-alanine at position 2 roughly halved metabolic clearance and extended the disappearance half-time from 4.3 to 6.7 minutes (Soule et al., 1994).
Asparagine deamidation at position 8 was the main route of degradation of an earlier analog in neutral aqueous solution (Friedman et al., 1991), which glutamine avoids, and leucine at position 27 removes an oxidation-prone methionine. Models: human plasma in vitro, enzyme kinetics, healthy volunteers and aqueous stability studies.
The version with DAC
The named compound CJC-1295 came out of a bioconjugation program: maleimido derivatives of the 1 to 29 fragment conjugated to serum albumin resisted dipeptidyl peptidase IV, stayed active in cultured rat pituitary cells, and in rats remained in plasma beyond 72 hours (Jetté et al., 2005).
In two placebo-controlled trials in healthy adults, that version raised mean growth hormone two to ten fold for six days or more, with an estimated half-life of 5.8 to 8.1 days (Teichman et al., 2006). Those figures belong to the albumin-binding version only. Models: rat cell culture, rats and healthy human adults.
The evidence gap for No DAC
A 2026 review of peptides acting on the growth hormone axis placed the form without the drug affinity complex in its lowest evidence tier: essentially uncharacterized in the peer-reviewed human literature, with no reported human half-life, its expected behavior inferred from the unmodified 1 to 29 fragment rather than measured (Dominikowski et al., 2026).
The substitutions above add minutes to hours of stability to a peptide cleared in minutes; they do not produce the multi-day profile of the version with DAC. A study citing the 5.8 to 8.1 day half-life while using No DAC material is citing the wrong molecule.
Pairing with a secretagogue
Releasing factor analogs are often studied alongside secretagogues such as ipamorelin because the two act through separate receptors. In rat pituitary cell culture, a secretagogue and the releasing factor gave a synergistic effect on growth hormone release at maximal concentrations; only the releasing factor raised cyclic AMP, and the two did not cross-desensitize (Cheng et al., 1989). That is an in-vitro rationale for combination designs, not evidence of a combined outcome. Model: rat cell culture.
Key studies
- Jetté L, et al. Endocrinology. 2005. PMID 15817669. Releasing factor 1 to 29 albumin bioconjugates: rat pituitary cells and rats.
- Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683. Placebo-controlled trials in healthy adults (version with DAC).
- Frohman LA, et al. J Clin Invest. 1986. PMID 3093533. Enzymatic degradation of the native releasing factor in plasma.
- Bongers J, et al. Biochim Biophys Acta. 1992. PMID 1353684. Dipeptidyl peptidase IV kinetics on the releasing factor and analogs.
- Soule S, et al. J Clin Endocrinol Metab. 1994. PMID 7962295. D-Ala2 substitution and half-life in healthy men.
- Friedman AR, et al. Int J Pept Protein Res. 1991. PMID 1904406. Degradation of releasing factor analogs in neutral aqueous solution.
- Cheng K, et al. Endocrinology. 1989. PMID 2541999. Rat pituitary cell culture: secretagogue and releasing factor synergy.
- Dominikowski A, et al. Front Endocrinol. 2026. PMID 42395176. Review of growth hormone axis peptides and their evidence tiers.
Handling and storage of lyophilized CJC-1295 No DAC
General laboratory practice for this material:
- Store the lyophilized powder at -20°C, protected from light, until use (storage guidance on the product page).
- Let the sealed vial reach room temperature before opening so moisture does not condense on the powder.
- Reconstitute in a sterile solvent or buffer suited to the assay, adding it gently down the vial wall and letting the powder dissolve without shaking: a 29-residue chain aggregates more readily under agitation and heat than a short peptide.
- After reconstitution keep solutions at 2 to 8°C and protected from light, and split stock into single-use aliquots to avoid freeze/thaw cycles.
- Record the lot number and take the molecular weight for molarity from the certificate.
Frequently asked questions
What is CJC-1295 No DAC?
A 29-residue, amidated analog of human growth hormone releasing factor (1 to 29) with four stabilizing substitutions and no albumin-binding group.
Is CJC-1295 No DAC the same as modified GRF 1-29?
Yes, the two names are used for the same substituted 1 to 29 fragment. Because names are used loosely, confirm identity by formula and molecular weight on the lot certificate.
CJC-1295 DAC vs No DAC: what is the difference?
The version with DAC carries a maleimide-bearing lysine that bonds to albumin, which is what gives it a half-life measured in days in human studies (Teichman et al., 2006). The No DAC form has no such group and no measured human half-life (Dominikowski et al., 2026). Our CJC-1295 DAC vs No DAC comparison covers it in full.
Does CJC-1295 No DAC have a long half-life?
Not as far as published data show. The multi-day figures in the literature belong to the albumin-binding version; the substitutions in the No DAC form extend stability from minutes to hours at most.
How should CJC-1295 No DAC powder be stored?
Keep the lyophilized powder at -20°C and protected from light. After reconstitution, store the solution at 2 to 8°C, protected from light, and avoid freeze/thaw cycles.
Where can researchers buy CJC-1295 No DAC?
Disguised Alpha sells it for laboratory research, third-party tested with the certificate published on the product page: CJC-1295 No DAC.
Related compounds and guides
- CJC-1295 DAC vs No DAC: research comparison
- CJC-1295 vs Ipamorelin: research comparison
- CJC-1295 with DAC
- Ipamorelin research guide
- CJC-1295 No DAC & Ipamorelin
- COA portal: every published certificate, by lot
This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.